News

Here, we will update important news and updates, listing them from most recent to least recent.

AstraZeneca COVID Vaccination

There may be concern about thrombosis relating to the AstraZeneca vaccine, but thrombosis experts are suggesting the continued use of the COVID19 vaccinations.

Read more here: https://isth.org/news/556057

Oral Anticoagulants on Children with Cardiac Disease

There are three trials on new oral anticoagulants on children with cardiac disease. You can find them below. I encourage patients and families to participate when possible.

Edoxaban: https://clinicaltrials.gov/ct2/show/NCT03395639?cond=Cardiac+Disease&intr=edoxaban&age=0&draw=2&rank=1

Rivaroxaban: https://clinicaltrials.gov/ct2/show/NCT02846532?cond=Fontan&intr=rivaroxaban&age=0&draw=2&rank=1

Apixaban: https://t.co/9Lpxwyyi65?amp=1

Rivaroxaban for VTE in pediatric patients

Xarelto (Rivaroxaban) is the first anticoagulant approved in Canada for treatment of venous thromboembolic events (VTE) and the prevention of VTE recurrence in pediatric patients (age birth to 18 years) based on the results of the EINSTEIN Jr program.

Canada is the first country in the world to give approval for this indication.Congratulations to all the children and the investigator team that made this happen and to Bayer for their commitment to the development of Xarelto to be used in children! 🎉

Rivaroxaban has also been granted for use in children by the European Medicines Agency (EMA) for VTE. Please consult the product monograph & familiarize yourself with the phase 3 publication (EINSTEIN-Jr study) in terms of exclusion criteria, especially in neonates.